

CLAIMS:

1. A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt, or a pharmaceutically acceptable solvate thereof, characterised in that the sodium salt is non-hygroscopic or slightly hygroscopic.
2. A compound according to claim 1, characterised in that it provides one or more of:
 - (i) an infrared spectrum substantially in accordance with Figure 1;
 - (ii) a Raman spectrum substantially in accordance with Figure 2;
 - (iii) an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3;
 - (iv) a Solid State ¹³C NMR spectrum substantially in accordance with Figure 4; and
 - (v) a melting point in the range of from 245 to 250°C.
3. A compound according to any one of claims 1 to 3, in a solid dosage form.
4. A compound according to any one of claims 1 to 4, in a bulk milled form.
5. A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt (the Sodium Salt) or a pharmaceutically acceptable solvate thereof, according to claim 1, wherein the Sodium Salt is present in an amount providing up to 12mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and a pharmaceutically acceptable carrier therefor.
6. A pharmaceutical composition according to claim 5, comprising the Sodium Salt or a pharmaceutically acceptable salt thereof in an amount providing 1, 2, 4, 8 or 12mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
7. A pharmaceutical composition according to claim 5, comprising the Sodium Salt or a pharmaceutically acceptable salt thereof in an amount providing 2mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
8. A pharmaceutical composition according to claim 5, comprising the Sodium Salt or a pharmaceutically acceptable salt thereof in an amount providing 4mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.

9. A pharmaceutical composition according to claim 5, in an amount providing 8mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
10. A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt or a pharmaceutically acceptable salt thereof in combination with one or more other anti-diabetic agents and optionally a pharmaceutically acceptable carrier therefor, wherein the Sodium Salt is present in an amount providing up to 12mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
11. A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt or a pharmaceutically acceptable salt thereof to a human or non-human mammal in need thereof, wherein the Sodium Salt is present in an amount providing up to 12mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
12. A method for a method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt or a pharmaceutically acceptable salt thereof in combination with one or more other anti-diabetic agents.
- 13.. A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, wherein the Sodium Salt is present in an amount providing up to 12mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
14. A use of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt or a solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, wherein the Sodium Salt is present in an amount providing up to 12mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.